Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > swing back between hope and frustration
View:
Post by DJDawg on Aug 20, 2023 7:52pm

swing back between hope and frustration

I swing back and forth on TLT so much. Some things give me hope and other things give me frustration. Hopeful attributes - great science by someone not directly employed by the company. Dr. MacFarland's work is amazing and separate so we are not just trusting some possibly misrepresented science from the company itself. Companies have been known to fudge science. - phase 1b results where 2/3 worst of the worst cancer patients were cured for good of their repeatedly recurring multifocal bladder cancer in one treatment. Followed for years of follow up and no recurrence. (That is what got me into TLT in the first place.)
- study is lead by someone not employed by TLT. All the study sites are also independent. Gives a bit of insulation from our well-founded concerns around competence by company management. - CR numbers beat most competitors. - most competitors have products that required many many instillations AND/OR IV therapy with side effects. - Med Adv Board is Dr. Kamat,  one of the leading names in Bladder Cancer and co-author on most of the recent posters presented. - TLT has done a phase 2 trial, so far, on quite a low budget compared to what most spend. - TLT appears to be debt free. - The insiders who know the most have always bought in when they can and have not sold a single share in years (if ever). This includes RDW and Dr. Mandel, the lead scientist. - they have the potential for IV version of their drug. - they have rights to a whole category of similar drugs that may work even better (for example, the uber-drug published a while ago) - low market cap and low share when I personally have bought shares. My own average is around 0.28. Not many promising biotech companies for which can buy in a such a low market cap. - the recent hire for the BOD who is medical, Boston based, American which is a nice addtion. Frustration and resentment from: - RDW's strange history of misrepresenting information and getting in trouble for it. - Vera's in and out hiring mess
- Shawn's abrupt departure
- Trikola's strange hiring and firing. - RDW's history of pointless litigation against internet trolls. - the constant prediction of imminent BTD and then the timeline being shifted again - the clumsy use of small hand to mouth PPs to get cash infusions (small cash each time, but enough to drop price back down to 0.235 when they are building). - the inability to get cash from a variety of sources such as licensing agreements, JV partnerships etc. anything other then all these PP's. All in all, I'm fine to keep longholding (like I have a choice) as I believe in the very unique science but not without feelings of frustration towards the management. Mainly for the clumsy use of PP's that are so small that they lead to another PP, months after the last one. If there is in fact another PP happening as per a previous poster. It will take some strong statements to convince people that they are done PP's at some point. If we all expect a new PP every few months, no one is going to bid up the price.

I feel that RDW consider this his baby and legacy. And that may be one reason he has not gotten outside money before now. Trying to do it on his own.

The only good thing about the PP (if there is one) is that any holders with some new cash can always buy a bit more at 0.235 to 0.25 if they are not on the invited list for the PP. That is a nice price to buy the dip even if it is so frustrating for the rest of us who are maxed our and holding.

All IMO
Comment by O12009 on Aug 20, 2023 8:42pm
You have hit the nail on the head. Hopefully by no later than the end of the month we get some very good news.
Comment by N0taP00p on Aug 20, 2023 8:59pm
Well said, DJDawg. I'd be happy if they condescended to tell us what the status of BTD submission is.   Based on the last raise, not many will bite on any further raises. We can only hope the next NR will be a yes or no from the FDA wrt BTD. 
Comment by FGPstock on Aug 21, 2023 1:15am
  djd, I think we are all in the same boat. Some more frustrated than others, but all hoping we picked a winner although some of the companies actions don't always make sense...  
Comment by chry200030 on Aug 21, 2023 8:50am
Why are people frustrated with TLT? Are they not currently in testing, and once testing is complete then FDA needs to review the results and approve or not approve.  I thought good progress was being made and we just have to wait for the process.  Once complete and the results are proven, then TLT should fly... 
Comment by ScienceFirst on Aug 21, 2023 11:02am
From an idea 13y ago to mid-Ph. 2 pivotal data that is superior on 6 key aspects to anything on the market, including the most recent competition, but apart from the market valuation, TLT management delivered on all fronts as we are awaiting the FDA decision for Breakthrough Therapy.  We even capture the interest of Canada's highest lab in Winnipeg with an unexpected indication (COVID-19) ...more  
Comment by N0taP00p on Aug 21, 2023 11:50am
You're a true legend. For your persistence in rehashing the same story many times a year and moving the goalposts, all while thinking no one will notice.  The difference now is that there are more savvy investors making their voices heard.  Keep at it. Keep us entertained. 
Comment by FGPstock on Aug 21, 2023 12:05pm
Same store, different year. SF/Bencro made the BTD prediction and revenue from AA to start 12/2022 - 1/2023. The more he talks the less credibility he has. soon he will just post 15B buyout comparisions, yet no one even knows is they applied for BTD, despite the company putting it in an NR 11/2022. It should b a 60 day process, not 9 months...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250